US HB3678 | 2015-2016 | 114th Congress
Status
Spectrum: Moderate Partisan Bill (Republican 9-2)
Status: Introduced on October 1 2015 - 25% progression, died in committee
Action: 2015-10-02 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on October 1 2015 - 25% progression, died in committee
Action: 2015-10-02 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Preserving Access to Orphan Drugs Act of 2015 This bill amends the Patient Protection and Affordable Care Act to expand the definition of orphan drug for purposes of the annual fee paid by brand name prescription drug manufacturers and importers to include medications for rare conditions that were, prior to 2011, approved or in clinical trials. (Drug manufacturers and importers pay an annual fee based on their sales of brand name prescription drugs, excluding sales of orphan drugs.) Currently, only medications for rare conditions for which a tax credit for clinical trials was allowed are considered orphan drugs. This Act applies to fees paid after 2014.
Title
Preserving Access to Orphan Drugs Act of 2015
Sponsors
Rep. Mike Kelly [R-PA] | Rep. Diane Black [R-TN] | Rep. Richard Neal [D-MA] | Rep. George Holding [R-NC] |
Rep. Charles Rangel [D-NY] | Rep. Lynn Jenkins [R-KS] | Rep. Patrick Tiberi [R-OH] | Rep. Kenny Marchant [R-TX] |
Rep. Devin Nunes [R-CA] | Rep. Mike Pompeo [R-KS] | Rep. Adam Kinzinger [R-IL] |
History
Date | Chamber | Action |
---|---|---|
2015-10-02 | House | Referred to the Subcommittee on Health. |
2015-10-01 | House | Referred to the Subcommittee on Health. |
2015-10-01 | House | Referred to House Energy and Commerce |
2015-10-01 | House | Referred to House Ways and Means |
2015-10-01 | House | Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2015-10-01 | House | Introduced in House |
Subjects
Drug safety, medical device, and laboratory regulation
Drug therapy
Health
Health care coverage and access
Prescription drugs
User charges and fees
Drug therapy
Health
Health care coverage and access
Prescription drugs
User charges and fees
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/114th-congress/house-bill/3678/all-info |
Text | https://www.congress.gov/114/bills/hr3678/BILLS-114hr3678ih.pdf |